EVOLUTION OF EASI RESPONSE WITH LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO- SEVERE ATOPIC DERMATITIS: POOLED RESULTS FROM TWO PHASE 3 TRIALS (ADVOCATE1 AND ADVOCATE2) AT WEEK 16

被引：0
|
作者：
Wollenberg, Andreas [1 ]
Warren, Richard B. [2 ]
Silverberg, Jonathan I. [3 ]
Guttman-Yassky, Emma [4 ]
Thaci, Diamant [5 ]
Irvine, Alan D. [6 ]
Gold, Linda Stein [7 ]
Blauvelt, Andrew [8 ]
Simpson, Eric L. [9 ]
Chu, Chia-Yu [10 ,11 ]
Liu, Zhuqing T. [12 ]
Lima, Renata Gontijo [12 ]
Pillai, Sreekumar [12 ]
Gil, Esther Garcia [13 ]
Seneschal, Julien [14 ,15 ]
机构：
[1] LMU Dept Dermatol & Allergol, Munich, Germany
[2] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester Nihr Biomed Res Ctr, Manchester, Lancs, England
[3] George Washington Univ, Dept Dermatol, Sch Med, Washington, DC USA
[4] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA
[5] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany
[6] Trinity Coll Dublin, Dept Clin Med, Dublin, Ireland
[7] Henry Ford Hlth Syst, Dermatol Clin Res, Detroit, MI USA
[8] Oregon Med Res Ctr, Portland, OR USA
[9] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR USA
[10] Natl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan
[11] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[12] Eli Lilly & Co, Indianapolis, IN USA
[13] Almirall SA, Barcelona, Spain
[14] Univ Bordeaux, Dept Dermatol, Bordeaux, France
[15] Hosp St Andre, Natl Reference Ctr Rare Skin Disorders, Dept Dermatol & Pediat Dermatol, Bordeaux, France
来源：
ACTA DERMATO-VENEREOLOGICA | 2023年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P10.9
引用
收藏
页码：53 / 53
页数：1
相关论文
共 50 条
  • [31] Bimekizumab response maintenance up to 1 year in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials
    Blauvelt, Andrew
    Tada, Yayoi
    Iversen, Lars
    Mrowietz, Ulrich
    Lebwohl, Mark
    Wang, Maggie
    Vanvoorden, Veerle
    Cullen, Eva
    Staelens, Fabienne
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB140 - AB140
  • [32] Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials
    Eric L. Simpson
    Dermatology and Therapy, 2017, 7 : 243 - 248
  • [33] Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials
    Simpson, Eric L.
    DERMATOLOGY AND THERAPY, 2017, 7 (02) : 243 - 248
  • [34] Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
    Gordon, Kenneth B.
    Langley, Richard G.
    Warren, Richard B.
    Okubo, Yukari
    Gold, Linda Stein
    Merola, Joseph F.
    Peterson, Luke
    Wixted, Krista
    Cross, Nancy
    Deherder, Delphine
    Thaci, Diamant
    JAMA DERMATOLOGY, 2022, 158 (07) : 735 - 744
  • [35] Dupilumab in Moderate-to-Severe Atopic Dermatitis With or Without Comorbid Asthma: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 & 2)
    Deleuran, Mette
    Guttman-Yassky, Emma
    Kingo, Kulli
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Akinlade, Bolanle
    Eckert, Laurent
    Gadkari, Abhijit
    Ardeleanu, Marius
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) : AB132 - AB132
  • [36] Interim results from ADmirable, a phase 3b open-label study assessing lebrikizumab in patients with skin of color and moderate-to-severe atopic dermatitis
    Alexis, Andrew
    Moiin, Ali
    Waibel, Jill
    Wallace, Paul
    Cohen, David
    Laquer, Vivian
    Kwong, Pearl
    Atwater, Amber Reck
    Harris, Cynthia
    Proper, Jennifer
    Silk, Maria
    Pierce, Evangeline
    Pillai, Sreekumar
    Rueda, Maria Jose
    Moore, Angela
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 102 - 103
  • [37] Maintenance of efficacy and safety with nemolizumab at week 48: results from two global phase 3 pivotal studies (ARCADIA-1 and ARCADIA-2) in patients with moderate-to-severe atopic dermatitis
    Silverberg, Jonathan, I
    Wollenberg, Andreas
    Legat, Franz J.
    Laquer, Vivian T.
    Armstrong, April W.
    Herranz, Pedro
    Naldi, Luigi
    Ahmad, Faiz
    Ulianov, Liliana
    Piketty, Christophe
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [38] Characterization of hematologic and transaminase laboratory findings associated with upadacitinib in moderate-to-severe atopic dermatitis: Results of two phase 3 trials (measure up 1 and 2)
    Silverberg, Jonathan I.
    Gooderham, Melinda J.
    de Bruin-Weller, Marjolein S.
    Papp, Kim A.
    Aoki, Valeria
    Paller, Amy S.
    Ofori, Sarah
    Tenorio, Allan R.
    Liu, Yingyi
    Liu, Jianzhong
    Chovatiya, Raj
    CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (08): : 1010 - 1010
  • [39] USE OF TOPICAL CORTICOSTEROIDS WITH TRALOKINUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM THE 32-WEEK, PHASE 3 ECZTRA 3 TRIAL
    Silverberg, Jonathan I.
    Pink, Andrew E.
    Kurbasic, Azra
    Olsen, Christina Kurre
    Weidinger, Stephan
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 55 - 55
  • [40] Dupilumab in Moderate-to-Severe Atopic Dermatitis With or Without Comorbid Allergic Rhinitis: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 & 2)
    Thaci, Diamant
    Bieber, Thomas R. M.
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Akinlade, Bolanle
    Eckert, Laurent
    Gadkari, Abhijit
    Ardeleanu, Marius
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) : AB136 - AB136
12345